noom med compounded semaglutide launches low dose of weight-loss drug for $119 Noom GLP-1 Access and Transparency

[79] While appetite suppression may influence the magnitude of reductions in food intake, three medical reviews indicate that lisdexamfetamine's enhancement of cognitive control is the primary therapeutic effect for reducing binge-eating symptoms and is likely required for addressing the disorder's underlying psychopathology

And honestly, we need to talk about its packaging

38 , e15268e15268 (2020)

While gene therapy is available for a small subset of patients with specific mutations, developing a therapeutic that broadly targets the cellular stresses that lead to cell death could address a major unmet need

The Drosophila surface glia transcriptome: evolutionary conserved bloodbrain barrier processes